The soluble ectodomain has been implicated as a decoy for ligand–receptor interactions in PTPRS signaling, with potential therapeutic applications in diseases such as cancer, Alzheimer’s disease, stroke, traumatic brain injury, and rheumatoid arthritis. This evidence concerns the gene PTPRS and early-onset autosomal dominant Alzheimer disease.